The Most Interesting Things Take Time
The world’s first approved product from monoclonal antibody technology was Muromonab-CD3 (Orthoclone OKT3), launched in 1986. It’s a prime example of “mAb version 1.0,” unleashed before a wave of newer, more manufacturable and better engineered products would begin to enter the market in the late-90s. Later molecular and process iterations based on “mAb 1.0” would take several decades to finally ramify into diverse platforms such as CAR-T, Bi-specific T-cell engagers (BiTEs), diagnostics, and biosensors. As a cellular technology platform, mesenchymal stem/stromal cells (MSCs) are proceeding with a story of convergent evolution. [Read more…]